<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35367069</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.</ArticleTitle><Pagination><StartPage>2705</StartPage><EndPage>2713</EndPage><MedlinePgn>2705-2713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.03.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00367-X</ELocationID><Abstract><AbstractText>Eradication of poliomyelitis globally is constrained by fecal shedding of live polioviruses, both wild-type and vaccine-derived strains, into the environment. Although inactivated polio vaccines (IPV) effectively protect the recipient from clinical poliomyelitis, fecal shedding of live virus still occurs following infection with either wildtype or vaccine-derived strains of poliovirus. In the drive to eliminate the last cases of polio globally, improvements in both oral polio vaccines (OPV) (to prevent reversion to virulence) and injectable polio vaccines (to improve mucosal immunity and prevent viral shedding) are underway. The E. coli labile toxin with two or "double" attenuating mutations (dmLT) may boost immunologic responses to IPV, including at mucosal sites. We performed a double-blinded phase I controlled clinical trial to evaluate safety, tolerability, as well as systemic and mucosal immunogenicity of IPV adjuvanted with dmLT, given as a fractional (1/5th) dose intradermally (fIPV-dmLT). Twenty-nine volunteers with no past exposure to OPV were randomized to a single dose of fIPV-dmLT or fIPV alone. fIPV-dmLT was well tolerated, although three subjects had mild but persistent induration and hyperpigmentation at the injection site. A ≥ 4-fold rise in serotype-specific neutralizing antibody (SNA) titers to all three serotypes was seen in 84% of subjects receiving fIPV-dmLT vs. 50% of volunteers receiving IPV alone. SNA titers were higher in the dmLT-adjuvanted group, but only differences in serotype 1 were significant. Mucosal immune responses, as measured by polio serotype specific fecal IgA were minimal in both groups and differences were not seen. fIPV-dmLT may offer a benefit over IPV alone. Beyond NAB responses protecting the individual, studies demonstrating the ability of fIPV-dmLT to prevent viral shedding are necessary. Studies employing controlled human infection models, using monovalent OPV post-vaccine are ongoing. Studies specifically in children may also be necessary and additional biomarkers of mucosal immune responses in this population are needed. Clinicaltrials.gov Identifer: NCT03922061.</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crothers</LastName><ForeName>Jessica W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA. Electronic address: Jessica.Crothers@uvmhealth.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross Colgate</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowan</LastName><ForeName>Kelly J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dorothy M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>MaryClaire</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmolli</LastName><ForeName>Marya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Peter F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Elizabeth B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, Tulane University, New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkpatrick</LastName><ForeName>Beth D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Microbiology and Molecular Genetics, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03922061</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R56 AI143937</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI153600</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Vaccine. 2022 May 31;40(25):3481. doi: 10.1016/j.vaccine.2022.05.001</RefSource><PMID Version="1">35534312</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054307" MajorTopicYN="Y">Enterotoxigenic Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvant</Keyword><Keyword MajorTopicYN="N">Injectable</Keyword><Keyword MajorTopicYN="N">Mucosal Immunity</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>3</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35367069</ArticleId><ArticleId IdType="pmc">PMC9024222</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.056</ArticleId><ArticleId IdType="pii">S0264-410X(22)00367-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rutter PD, Hinman AR, Hegg L, King D, Sosler S, Swezy V, et al., Transition Planning For After Polio Eradication. J Infect Dis 2017;216:S287–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853549</ArticleId><ArticleId IdType="pubmed">28838183</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. World Health Organization Weekly Epidemiological Record. Polio Vaccines: WHO Position Paper-March 2016. In: World Health Organization Weekly Epidemiological Record. Polio Vaccines: WHO Position Paper-March 2016. https://www.who.int/wer/2016/wer9112.pdf?ua=1.</Citation></Reference><Reference><Citation>Organization WH Africa eradicates wild poliovirus. In: Africa eradicates wild poliovirus. https://www.afro.who.int/news/africa-eradicates-wild-poliovirus.</Citation></Reference><Reference><Citation>Faden H., Modlin J.F., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162(6):1291–1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">2172403</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt L.R., Estivariz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(suppl 1):S380–S389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283–S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman M.M., Jorba J., Greene S.A., Diop O.M., Iber J., Tallis G., et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020. Morbidity Mortal Wkly Rep. 2020;69(16):489–495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin J, Ottosen A, Ghazieh A, Fournier-Caruana J, Ntow AK, Gonzalez AR. Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market. J Infect Dis 2017;216:S40–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853836</ArticleId><ArticleId IdType="pubmed">28838167</ArticleId></ArticleIdList></Reference><Reference><Citation>John J., Giri S., Karthikeyan A.S., Iturriza-Gomara M., Muliyil J., Abraham A., et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet Lond Engl. 2014;384(9953):1505–1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">25018120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright P.F., Connor R.I., Wieland-Alter W.F., Hoen A.G., Boesch A.W., Ackerman M.E., et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377–1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5611465</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari H., Deshpande J.M., Sutter R.W., Bahl S., Verma H., Ahmad M., et al. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345(6199):922–925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias E.J., Bandyopadhyay A.S., Self S., Rivera L., Saez-Llorens X., Lopez E., et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet Lond Engl. 2016;388(10040):158–169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, et al. Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine. J Infect Dis 2018;218:1876–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161111</ArticleId><ArticleId IdType="pubmed">29982532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. Plos Pathog. 2012;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans T.M., Reimerink J.H., Buisman A.M., Kimman T.G. Koopmans MP (1999) Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol Baltim Md. 1950;162:5011–5018.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202050</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M., Selinger C., McCarthy K.A., Eckhoff P.A., Chabot-Couture G., Riley S. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. Plos Biol. 2018;16(4):e2002468. doi: 10.1371/journal.pbio.2002468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2002468</ArticleId><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K.M., Tebbens R.J.D. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017;216:S176–S182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant escherichia coli heat-labile Toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol. 2011;18(4):546–551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122563</ArticleId><ArticleId IdType="pubmed">21288994</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements J.D., Norton E.B., Papasian C.J. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT. mSphere. 2018;3(4) doi: 10.1128/mSphere.00215-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00215-18</ArticleId><ArticleId IdType="pmc">PMC6060342</ArticleId><ArticleId IdType="pubmed">30045966</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton E.B., Bauer D.L., Weldon W.C., Oberste M.S., Lawson L.B., Clements J.D. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909–1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">25765967</ArticleId></ArticleIdList></Reference><Reference><Citation>White J.A., Blum J.S., Hosken N.A., Marshak J.O., Duncan L., Zhu C., et al. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccin Immunother. 2014;10(12):3611–3621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514067</ArticleId><ArticleId IdType="pubmed">25483682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T., Gutiérrez R.L., Maciel M., Poole S., Testa K.J., Trop S., et al. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine. 2021;39(39):5548–5556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461560</ArticleId><ArticleId IdType="pubmed">34419306</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Kamary S.S., Cohen M.B., Bourgeois A.L., Van De Verg L., Bauers N., Reymann M., et al. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol. 2013;20(11):1764–1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837789</ArticleId><ArticleId IdType="pubmed">24049109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein D.I., Pasetti M.F., Brady R., Buskirk A.D., Wahid R., Dickey M., et al. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Vaccine. 2019;37(4):602–611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331259</ArticleId><ArticleId IdType="pubmed">30563789</ArticleId></ArticleIdList></Reference><Reference><Citation>Svennerholm A.M., Qadri F., Lundgren A., Kaim J., Rahman Bhuiyan T., Akhtar M., et al. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants. Vaccine. 2021 Nov 9:S0264–410X(21)01389-X.</Citation><ArticleIdList><ArticleId IdType="pubmed">34772542</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick D.R., Goggins J.A., Sabbagh L.M., Freytag L.C., Clements J.D., McLachlan J.B. Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+ T cells following parenteral immunization. Mucosal Immunol. 2018;11(2):549–561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6252260</ArticleId><ArticleId IdType="pubmed">28792004</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciel M., Bauer D., Baudier R.L., Bitoun J., Clements J.D., Poole S.T., et al. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli. Infect Immun. 2019;87(11) doi: 10.1128/IAI.00460-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00460-19</ArticleId><ArticleId IdType="pmc">PMC6803349</ArticleId><ArticleId IdType="pubmed">31427449</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciel M., Smith M., Poole S.T., Laird R.M., Rollenhagen J.E., Kaminski R.W., et al. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice. PLoS One. 2019;14(11):e0224073. doi: 10.1371/journal.pone.0224073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0224073</ArticleId><ArticleId IdType="pmc">PMC6827915</ArticleId><ArticleId IdType="pubmed">31682624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E., A Supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis 2017;216:S33–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H, Sein C, Blanc DC, Gonzalez AR, Zehrung D, Jarrahian C, et al., Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216:S161–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853966</ArticleId><ArticleId IdType="pubmed">28838185</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciel M., Smith M., Poole S.T., Laird R.M., Rollenhagen J.E., Kaminski R.W., et al. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice. PLoS One. 2019;14(11):e0224073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827915</ArticleId><ArticleId IdType="pubmed">31682624</ArticleId></ArticleIdList></Reference><Reference><Citation>Javier Martín (Ed.), Poliovirus: Methods and Protocols, Methods in Molecular Biology, vol. 1387, DOI 10.1007/978-1-4939-3292-4_8, © Springer Science+Business Media New York 2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_8</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Wieland-Alter W, Ilyushina NA, et al., Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis 2014;209:1628–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24459191</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I., Leroux-Roels I., Bandyopadhyay A.S., Gast C., Withanage K., Steenackers K., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T.D., DeAntonio R., Jimeno J., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel B.U., Cherian T., Sridharan G., Mukundan P., John T.J. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet. 1991;338(8763):343–344.</Citation><ArticleIdList><ArticleId IdType="pubmed">1677699</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel B.U., Cherian T., Rajasingh J., Raghupathy P., John T.J. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine. 1992;10(2):135. doi: 10.1016/0264-410X(92)90039-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(92)90039-M</ArticleId><ArticleId IdType="pubmed">1311491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmal S., Cherian T., Samuel B.U., Rajasingh J., Raghupathy P., John T.J. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine. 1998;16(9–10):928–931.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino N., Kanekiyo M., Hagiwara Y., Okamura T., Someya K., Matsuo K., et al. Intradermal delivery of recombinant vaccinia virus vector DIs induces gutmucosal immunity. Scand J Immunol. 2010;72(2):98–105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20618768</ArticleId></ArticleIdList></Reference><Reference><Citation>Enioutina E.Y., Visic D., Daynes R.A. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine. 2000;18(24):2753–2767.</Citation><ArticleIdList><ArticleId IdType="pubmed">10781863</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich J., Andreasen L.V., Andersen P., Agger E.M., Rodrigues M.M. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100879</ArticleId><ArticleId IdType="pmc">PMC4067388</ArticleId><ArticleId IdType="pubmed">24956110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren A., Bourgeois L., Carlin N., Clements J., Gustafsson B., Hartford M., et al. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine. 2014;32(52):7077–7084. doi: 10.1016/j.vaccine.2014.10.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.10.069</ArticleId><ArticleId IdType="pubmed">25444830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Quddus A., et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019. Mmwr Morbidity Mortal Wkly Rep. 2019;68(45):1024–1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, Strauch CB, Wieland-Alter WF, et al., Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis 2018;217:371–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley E.B., Connor R.I., Wieland-Alter W.F., Collett M.S., Hartford M., Van Der Avoort H., et al. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. Bmj Global Heal. 2019;4(4):e001613. doi: 10.1136/bmjgh-2019-001613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2019-001613</ArticleId><ArticleId IdType="pmc">PMC6730592</ArticleId><ArticleId IdType="pubmed">31543993</ArticleId></ArticleIdList></Reference><Reference><Citation>Senda T., Dogra P., Granot T., Furuhashi K., Snyder M.E., Carpenter D.J., et al. Microanatomical dissection of human intestinal T-cell immunity reveals site-specific changes in gut-associated lymphoid tissues over life. Mucosal Immunol. 2019;12(2):378–389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375790</ArticleId><ArticleId IdType="pubmed">30523311</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome J.J.C., Bickham K.L., Ohmura Y., Kubota M., Matsuoka N., Gordon C., et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med. 2016;22(1):72–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703455</ArticleId><ArticleId IdType="pubmed">26657141</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespo M., Martinez D.G., Cerissi A., Rivera-Reyes B., Bernstein H.B., Lederman M.M., et al. Neonatal T-cell maturation and homing receptor responses to Toll-like receptor ligands differ from those of adult naive T cells: relationship to prematurity. Pediatr Res. 2012;71(2):136–143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394681</ArticleId><ArticleId IdType="pubmed">22258123</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor R.I., Brickley E.B., Wieland-Alter W.F., Ackerman M.E., Weiner J.A., Modlin J.F., et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8732262</ArticleId><ArticleId IdType="pubmed">34239028</ArticleId></ArticleIdList></Reference><Reference><Citation>Din M., Asghar M., Ali M. Delays in polio vaccination programs due to COVID-19 in Pakistan: a major threat to Pakistan’s long war against polio virus. Public Health. 2020;189:1–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7552970</ArticleId><ArticleId IdType="pubmed">33065398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>